Loading
Led PERSEPHONE, which showed six months of trastuzumab is nearly as good as twelve for most patients.
Helena Earl was chief investigator of PERSEPHONE, the 4,000-patient UK trial showing six months of adjuvant trastuzumab is non-inferior to twelve months with less cardiotoxicity, and of the neoadjuvant ARTemis and Neo-tAnGo trials. Her work anchors the de-escalation debate in HER2-positive early breast cancer.
Shares Trastuzumab, HER2, HER2-positive breast cancer and the tags breast, her2.
Shares Cancer Research UK Cambridge Centre / CRUK Cambridge Institute and the tags breast, de-escalation.
Shares HER2, HER2-positive breast cancer and the tags breast, her2.
Shares HER2, HER2-positive breast cancer and the tags breast, her2.
Shares HER2-positive breast cancer and the tags breast, de-escalation.
Shares PERSEPHONE, Trastuzumab, HER2-positive breast cancer.
Shares HER2-positive breast cancer and the tags breast, de-escalation.
Shares Cancer Research UK Cambridge Centre / CRUK Cambridge Institute, HER2-positive breast cancer and the tag breast.